Sesen Bio (NASDAQ: SESN) is a late-stage clinical corporation that develops fusion protein therapeutics designed to treat cancer patients which recently announced that its Board of directors would have new members. The people appointed were Global Regulatory Affairs Head and former SVP at Pfizer, Dr. Peter Honig and practicing Oncologist, Dr. Michael Jewett, FACS, FRCSC. Sesen’s BLA (Biologics License Application) for Vicineum, the lead program of the company, is currently undergoing the FDA’s Priority Review for the non-muscle invasive, BCG-unresponsive bladder cancer treatment in the United States.
Sesen’s President and Chief Executive Officer, Dr. Thomas Cannell, said that they were delighted to welcome both Dr. Michael Jewett and Dr. Peter Honig to their Board of Directors team. He said that the company is at a transformational stage as it approaches the potential launch of its Vicineum program in the United States. Dr. Cannell expressed how fortunate Sesen was to be adding Dr. Honig’s global regulatory experience and Dr. Jewett’s extensive clinical expertise to the Board. These two individuals’ wealth of experience will prove invaluable to the company as it continues to try and inject its potentially top-in-class treatment to the global market.
Dr. Honig is an experienced leader and top-class professional in the tactical and strategic aspects of vaccine and medicine development with specific expertise in medical product regulation, medical product safety, compliance, setting clinical trial design, clinical programs and clinical pharmacology. Dr. Honig is a former SVP and Global Regulatory Affairs Head at Pfizer. He worked across the company to ensure quality control, compliance and regulatory effectiveness throughout all the post-approval and product development stages. In doing this, he helped ensure Pfizer kept up with its commitment to patient safety.
Dr. Honig has also been a PhRMA rep to the ICH (International Conference Harmonisation) Steering Committee for about 19 years. He is also a former ASCPT (American Society for Clinical Pharmacology and Therapeutics) President. Dr. Honig said he was delighted to be joining Sesen’s Board of Directors and is looking forward to helping them grow in the future.